RxDoctor Payments DataLook up a doctor →

Surindar Jolly, MD

Vascular Neurology · Wayne, MINPI 1164479911

Payments from drug & device makers

$25,007in general payments, 2019–2025

Across 842 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sarepta Therapeutics, Inc.$7K
  • UCB, Inc.$3K
  • Amneal Pharmaceuticals LLC$2K
  • Biogen$1K
  • Bristol Myers Squibb$1K
  • EMD Serono, Inc.$738
  • plus $10K from 50 others

What the payments were for

  • Consulting fees$5,61022%
  • Speaking & faculty fees$1,7457%
  • Travel & lodging$1,3515%
  • Food & beverage$16,12464%
  • Education$1771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sarepta Therapeutics, Inc.6$7,053
UCB, Inc.147$2,754
Amneal Pharmaceuticals LLC16$2,117
Biogen66$1,295
Bristol Myers Squibb75$1,163
EMD Serono, Inc.40$738
Teva Pharmaceuticals USA, Inc.42$723
SK Life Science, Inc.36$655
Neurocrine Biosciences, Inc.24$615
Novartis45$615
Eisai Inc.19$595
Neurelis, Inc.24$571
AbbVie(2 entities)21$516
E.r. Squibb & Sons, L.L.C.7$504
Amgen(2 entities)21$448
Argenx US, Inc.22$403
AstraZeneca(2 entities)17$370
Johnson & Johnson10$320
Sunovion Pharmaceuticals Inc.19$312
Supernus Pharmaceuticals, Inc.53$267
Pfizer13$240
Axsome Therapeutics, Inc.4$220
Harmony Biosciences LLC10$219
Kyowa Kirin, Inc.6$205
Lilly USA, LLC12$203
Sanofi8$164
Jazz Pharmaceuticals Inc.6$141
Otsuka America Pharmaceutical, Inc.7$140
Genentech USA, Inc.6$132
Portola Pharmaceuticals, LLC1$130
Catalyst Pharmaceuticals, Inc.7$114
Avanir Pharmaceuticals, Inc.6$110
Lundbeck LLC5$91
Livanova USA, Inc.4$85
Aucta Pharmaceuticals, Inc.5$83
Promius Pharma LLC1$62
Tanabe Pharma America, Inc.3$60
TG Therapeutics, Inc.2$58
MDD US Operations, LLC3$55
Adamas Pharmaceuticals, Inc.3$46
Nevro Corp.1$44
Scilex Pharmaceuticals Inc.2$44
Biohaven Pharmaceuticals, Inc.2$40
Greenwich Biosciences, Inc.2$38
Aprecia Pharmaceuticals, LLC2$32
Takeda Pharmaceuticals U.S.A., Inc.1$29
Octapharma USA, Inc.1$28
Sumitomo Pharma America, Inc.1$23
OWP Pharmaceuticals, Inc.1$20
Azurity Pharmaceuticals, Inc.1$19
Alnylam Pharmaceuticals Inc.1$19
Sanofi-aventis U.S. LLC1$19
Hospira, Inc.1$19
Acadia Pharmaceuticals Inc1$16
Zogenix Inc.1$13
Biohaven Pharmaceutical Holding Company Ltd.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,007 in reported general payments places this provider in the 75th percentile of 29 vascular neurology providers in Michigan.

See all vascular neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$313,285
Medicare patients
465
Services billed
2,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a30$264,651
VumerityDiroximel Fumarate12$103,600
GlatopaGlatiramer Acetate14$59,284
AustedoDeutetrabenazine11$40,490
XcopriCenobamate22$28,188
BriviactBrivaracetam15$24,787
Pregabalin310$11,137
Levetiracetam348$11,111
DilantinPhenytoin Sodium Extended32$6,774
Clobazam39$5,292
Lacosamide70$5,204
Gabapentin417$5,037
TegretolCarbamazepine11$4,838
Carbidopa-LevodopaCarbidopa/Levodopa148$4,265
Carbamazepine74$4,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,295$103,60012 claims
Teva Pharmaceuticals USA, Inc.Austedo$723$40,49011 claims
SK Life Science, Inc.Xcopri$655$28,18822 claims
UCB, Inc.Briviact$2,754$24,78715 claims
PfizerDilantin$240$6,77432 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$2,117$1,52817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 29 vascular neurology providers in Michigan.

Other vascular neurology in Wayne

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →